MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 576864 | Name: Manitimus
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Manitimus is an inhibitor of dehydroorotate dehydrogenase and immunosuppresant.

Chemical Structure

Manitimus
Manitimus
CAS#202057-76-9

Theoretical Analysis

MedKoo Cat#: 576864

Name: Manitimus

CAS#: 202057-76-9

Chemical Formula: C15H11F3N2O2

Exact Mass: 308.0773

Molecular Weight: 308.26

Elemental Analysis: C, 58.45; H, 3.60; F, 18.49; N, 9.09; O, 10.38

Price and Availability

Size Price Availability Quantity
5mg USD 750.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
No Data
Synonym
Manitimus; FK778
IUPAC/Chemical Name
2-Hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-, (Z)-
InChi Key
IRELROQHIPLASX-SEYXRHQNSA-N
InChi Code
InChI=1S/C15H11F3N2O2/c1-2-3-4-13(21)12(9-19)14(22)20-11-7-5-10(6-8-11)15(16,17)18/h1,5-8,21H,3-4H2,(H,20,22)/b13-12-
SMILES Code
O\C(=C(\C#N)/C(=O)Nc1ccc(cc1)C(F)(F)F)\CCC#C
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
To be determined
Shelf Life
>2 years if stored properly
Drug Formulation
To be determined
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 308.26 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Fitzsimmons WE, First MR. FK778, a synthetic malononitrilamide. Yonsei Med J. 2004 Dec 31;45(6):1132-5. doi: 10.3349/ymj.2004.45.6.1132. PMID: 15627308. 2: Fawcett J, Johnson DW. FK778: a powerful immunosuppressive, but will it really be good for you? Transplantation. 2004 Jul 15;78(1):7-8. doi: 10.1097/01.tp.0000132563.08111.88. PMID: 15257031. 3: Deuse T, Schrepfer S, Schäfer H, Koch-Nolte F, Schwedhelm E, Böger RH, Reichenspurner H. FK778 attenuates lymphocyte-endothelium interaction after cardiac transplantation: in vivo and in vitro studies. Transplantation. 2004 Jul 15;78(1):71-7. doi: 10.1097/01.tp.0000128629.53843.14. PMID: 15257041. 4: Alessiani M, Abbiati F, Zonta S, Zitelli E, Bardone M, Cobianchi L, Viganò J, Doni M, Mazzilli M, Dominioni T, Kabiri D, Bottazzi A, Morbini P, Molinaro MD, Dionigi P. FK778 and tacrolimus combination therapy to control acute rejection after pig intestinal transplantation. Transplant Proc. 2006 Jul- Aug;38(6):1809-11. doi: 10.1016/j.transproceed.2006.05.042. PMID: 16908288. 5: Yamamoto S, Okuda T, Yamasaki K, Tanaka H, Kubo S, Takemura S, Ikeda K, Minamiyama Y, Hirohashi K, Suehiro S. FK778 and FK506 combination therapy to control acute rejection after rat liver allotransplantation. Transplantation. 2004 Dec 15;78(11):1618-25. doi: 10.1097/01.tp.0000144312.08782.16. PMID: 15591950. 6: Kloppenburg G, de Graaf R, Grauls G, Bruggeman CA, van Hooff JP, Stassen F. FK778 attenuates cytomegalovirus-enhanced vein graft intimal hyperplasia in a rat model. Intervirology. 2009;52(4):189-95. doi: 10.1159/000225194. Epub 2009 Jun 17. PMID: 19546576. 7: Deuse T, Schrepfer S, Koch-Nolte F, Haddad M, Schwedhelm E, Böger R, Schäfer H, Detter C, Reichenspurner H. FK778 and tacrolimus prevent the development of obliterative airway disease after heterotopic rat tracheal transplantation. J Heart Lung Transplant. 2005 Nov;24(11):1844-54. doi: 10.1016/j.healun.2005.03.005. Epub 2005 Jul 27. PMID: 16297791. 8: Rintala JM, Savikko J, Rintala SE, von Willebrand E. FK778 ameliorates post- transplant expression of fibrogenic growth factors and development of chronic rejection changes in rat kidney allografts. Nephrol Dial Transplant. 2008 Nov;23(11):3446-55. doi: 10.1093/ndt/gfn340. Epub 2008 Jun 16. PMID: 18558624. 9: Pan F, Ebbs A, Wynn C, Erickson L, Jang MS, Crews G, Fisniku O, Kobayashi M, Paul LC, Benediktsson H, Jiang AH. FK778, a powerful new immunosuppressant, effectively reduces functional and histologic changes of chronic rejection in rat renal allografts. Transplantation. 2003 Apr 27;75(8):1110-4. doi: 10.1097/01.TP.0000063704.19149.E3. PMID: 12717186. 10: Schrepfer S, Deuse T, Koch-Nolte F, Krieger T, Haddad M, Schäfer H, Pelletier MP, Robbins RC, Reichenspurner H. FK778 in experimental xenotransplantation: a detailed analysis of drug efficacy. J Heart Lung Transplant. 2007 Jan;26(1):70-7. doi: 10.1016/j.healun.2006.10.013. PMID: 17234520. 11: Schrepfer S, Deuse T, Koch-Nolte F, Detter C, Reichenspurner H. FK778: new cellular and molecular mechanisms of action. Transplant Proc. 2006 Apr;38(3):757-61. doi: 10.1016/j.transproceed.2006.01.058. PMID: 16647464. 12: Deuse T, Schrepfer S, Pelletier MP, Fischbein MP, Robbins RC, Reichenspurner H. Is the malononitrilamide FK778 better for the prevention of acute or chronic rejection? Transplant Proc. 2007 Mar;39(2):569-72. doi: 10.1016/j.transproceed.2006.12.020. PMID: 17362784. 13: Vu MD, Qi S, Wang X, Jiang W, Ma A, Xu D, Bekersky I, Fitzsimmons WE, Wu J, Chen H. Combination therapy of malononitrilamide FK778 with tacrolimus on cell proliferation assays and in rats receiving renal allografts. Transplantation. 2003 May 15;75(9):1455-9. doi: 10.1097/01.TP.0000058811.25785.F4. PMID: 12792496. 14: Jin MB, Nakayama M, Ogata T, Fujita M, Mino K, Taniguchi M, Suzuki T, Shimamura T, Furukawa H, Todo S. A novel leflunomide derivative, FK778, for immunosuppression after kidney transplantation in dogs. Surgery. 2002 Jul;132(1):72-9. doi: 10.1067/msy.2002.125390. PMID: 12110798. 15: Vanrenterghem Y, van Hooff JP, Klinger M, Wlodarczyk Z, Squifflet JP, Mourad G, Neuhaus P, Jurewicz A, Rostaing L, Charpentier B, Paczek L, Kreis H, Chang R, Paul LC, Grinyó JM, Short C. The effects of FK778 in combination with tacrolimus and steroids: a phase II multicenter study in renal transplant patients. Transplantation. 2004 Jul 15;78(1):9-14. doi: 10.1097/01.tp.0000132562.54089.62. PMID: 15257032. 16: Yamamoto S, Okuda T, Yamasaki K, Tanaka H, Takemura S, Minamiyama Y, Ikeda K, Hirohashi K, Suehiro S. FK778 controls acute rejection after rat liver allotransplantation showing positive interaction with FK506. Transplant Proc. 2005 Jan-Feb;37(1):126-9. doi: 10.1016/j.transproceed.2005.02.016. PMID: 15808570. 17: Millán O, Jiménez O, Fortuna V, Barceló JJ, Brunet M. Role of FK778 alone or in combination with tacrolimus or mTOR inhibitors as an immunomodulator of immunofunctions: in vitro evaluation of T cell proliferation and the expression of lymphocyte surface antigens. Int J Immunopathol Pharmacol. 2006 Apr- Jun;19(2):317-30. PMID: 16831299. 18: Deuse T, Schrepfer S, Reichenspurner H. Immunosuppression with FK778 and mycophenolate mofetil in a rat cardiac transplantation model. Transplantation. 2003 Dec 15;76(11):1627-9. doi: 10.1097/01.TP.0000092006.43818.B0. PMID: 14702537. 19: Birnbaum F, Schwartzkopff J, Scholz C, Reis A, Reinhard T. The new malononitrilamide immunosuppressant FK778 prolongs corneal allograft survival in the rat keratoplasty model. Eye (Lond). 2007 Dec;21(12):1516-23. doi: 10.1038/sj.eye.6702727. Epub 2007 Mar 30. PMID: 17401326. 20: Lutz J, Huang H, Deng M, Wagner B, Roos M, Schmaderer C, Strobl M, Heemann U. The effect of FK778 on the progression of chronic allograft nephropathy in a rat model. Transplantation. 2007 Mar 27;83(6):741-6. doi: 10.1097/01.tp.0000255558.02582.ce. PMID: 17414707.